Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 113 followers
Latest posts
Last updated about 5 hours ago
Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis
about 5 hours ago
Omvoh now offers patients a simplified maintenance experience with one monthly injection...
Lilly declares fourth-quarter 2025 dividend
about 7 hours ago
INDIANAPOLIS , Oct. 27, 2025 /PRNewswire/ -- The board of directors of...
Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea
about 8 hours ago
Basketball legend, entrepreneur and entertainer Shaquille O'Neal partners with Lilly to shine...
Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis
about 15 hours ago
Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to...
Lilly to Acquire Adverum Biotechnologies
4 days ago
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to...
Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
4 days ago
This trial is the first and largest study specifically designed to evaluate...
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis
4 days ago
New long-term extension data show approximately 80% of patients achieved or maintained...
Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
11 days ago
Verzenio is the first contemporary therapy in over two decades to demonstrate...
Lilly confirms date and conference call for third-quarter 2025 financial results announcement
11 days ago
INDIANAPOLIS , Oct. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
13 days ago
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8%...
Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
15 days ago
Primary overall survival analysis from the Phase 3 monarchE study of Verzenio...
WHO Foundation and Lilly Collaborate to Support Global Dementia Action Plan
15 days ago
Berlin, October 13, 2025 -- The WHO Foundation and Lilly have announced...